Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis-Reference-Cited by-同舟云学术

Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis

Published:2022-12-19 Issue:1 Volume:25 Page:67-77
ISSN:1174-5878
Container-title:Pediatric Drugs
language:en
Short-container-title:Pediatr Drugs

Author:

Paller Amy S.^ORCID,Siegfried Elaine C.,Cork Michael J.,Wollenberg Andreas^ORCID,Arkwright Peter D.^ORCID,Gonzalez Mercedes E.^ORCID,Lockshin Benjamin,Chen Zhen,Bansal Ashish,Levit Noah A.^ORCID,Prescilla Randy^ORCID

Funder

Sanofi and Regeneron Pharmaceuticals, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pediatrics, Perinatology and Child Health

Link

https://link.springer.com/content/pdf/10.1007/s40272-022-00553-8.pdf

Reference38 articles.

1. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. https://doi.org/10.1038/s41572-018-0001-z.

2. Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519–31. https://doi.org/10.1016/j.jaip.2017.08.005.

3. Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768–75. https://doi.org/10.1111/bjd.15928.